One of the world’s largest diagnostic laboratory companies spent 2025 doing something worth watching.
It was not simply opening more laboratories.
It was making deals.
Labcorp reported that it signed or closed 13 transactions with health systems and regional or local laboratories during 2025 as part of its strategy to become a preferred diagnostic partner for healthcare providers. (Labcorp 2025 Annual Report)
Not all of those transactions were acquisitions. They included a combination of laboratory asset purchases, partnerships and operating arrangements.
But the direction is clear.
For one of the world’s largest laboratory groups, consolidation and partnership have become important tools for growth.
Labcorp generated approximately US$13.95 billion in revenue in 2025, compared with US$13.01 billion in 2024. Yet despite already operating at enormous scale, the company continues to acquire laboratory assets and build relationships with hospital systems.
Why?
The answer provides an important lesson about the economics of the diagnostic laboratory industry.
And it may eventually become highly relevant to developing diagnostic markets such as Vietnam.
Labcorp’s US$14 Billion Business Is Still Buying Laboratory Assets
Two transactions illustrate the scale of Labcorp’s strategy.
In July 2025, Labcorp agreed to acquire selected outpatient laboratory assets from Community Health Systems across 13 US states for US$195 million in cash. (Labcorp – Community Health Systems transaction)
The transaction included selected patient service centres and in-office blood collection locations associated with Community Health Systems.
When the transaction was completed in December, the final disclosed consideration was approximately US$194 million before certain transaction expenses.
Importantly, Community Health Systems did not sell all of its laboratory operations.
Its hospitals continued operating inpatient and emergency department laboratories and continued providing laboratory services required for hospital-based activities.
What changed was the outpatient laboratory business.
In effect, Community Health Systems retained laboratory capabilities closely connected with hospital care while transferring part of its broader outpatient testing network to a specialised laboratory operator.
Another transaction followed a similar logic.
Labcorp acquired selected oncology and related clinical-testing assets from BioReference Health in a transaction valued at up to US$225 million. (Labcorp – BioReference Health acquisition)
The acquisition included US$192.5 million paid at closing and up to US$32.5 million in additional payments based on performance.
The acquired operations generated approximately US$85 million to US$100 million in annual revenue and strengthened Labcorp’s position in oncology testing.
These are not simply purchases of laboratory equipment.
They represent the acquisition of testing volume, customer relationships, specialised capabilities and access to healthcare networks.
That distinction is important.
Why Would a US$14 Billion Company Keep Buying Laboratories?
Scale is one of the central economic advantages in diagnostic testing.
A large laboratory network already has substantial infrastructure in place.
It has analyzers.
It has specialist testing platforms.
It has pathologists, laboratory professionals and technical expertise.
It has logistics systems capable of transporting samples between collection points and central laboratories.
It has digital infrastructure for ordering tests, tracking samples and reporting results.
And increasingly, it has specialised capabilities in areas such as molecular diagnostics, genetics, oncology and advanced pathology.
Once that infrastructure exists, adding more testing volume to the network can improve the economics of the platform.
A new laboratory acquisition does not necessarily require Labcorp to recreate every capability from the beginning.
Instead, acquired samples and customers can potentially be connected to infrastructure that already exists.
This is one reason why scale matters so much in laboratory diagnostics.
The more efficiently a laboratory can utilise its equipment, specialists, logistics network and technology platform, the more effectively it can spread fixed costs across a larger testing base.
Laboratory M&A Is About Volume — But Not Only Volume
Testing volume is clearly valuable.
However, laboratory acquisitions can create several other strategic benefits.
One is geographic density.
Adding collection centres and healthcare relationships in a region can improve the economics of sample transportation. A denser network may allow more samples to move through existing logistics routes and into central laboratories.
Another is specialised testing capability.
The BioReference transaction, for example, strengthened Labcorp’s position in oncology. Instead of acquiring only routine laboratory volume, Labcorp gained businesses focused on cancer-related testing.
A third advantage is customer relationships.
Laboratory businesses are connected to hospitals, physician groups, clinics and patients. Acquiring selected laboratory operations may therefore provide immediate access to established referral relationships that could take years to develop organically.
Finally, acquisitions can create opportunities to introduce a broader menu of tests to an existing customer base.
A regional laboratory may provide routine testing efficiently but have limited access to highly specialised diagnostics.
After becoming connected with a larger platform, those same physicians and healthcare providers can potentially access a much wider range of tests.
This creates an important network effect.
The value of a laboratory platform can increase as more testing volume, healthcare relationships and specialist capabilities are connected to it.
Hospitals May Not Want to Own Every Laboratory Capability
There is another important factor behind laboratory consolidation.
Hospitals have limited capital.
They need to invest in clinical services, medical equipment, facilities, digital systems and patient care.
Laboratory technology competes with all of these priorities for investment.
Labcorp itself identifies this trend in its corporate strategy.
The company says it expects hospitals, health systems and other laboratories to increasingly focus investment on core patient-care services while looking for partners capable of providing comprehensive testing services.
This creates a strategic question for hospital operators.
Which laboratory functions genuinely need to remain inside the hospital?
And which could potentially be provided more efficiently through an external diagnostic partner?
Urgent inpatient testing will often remain inside the hospital because turnaround time is critical.
But some outpatient, specialised and lower-frequency tests may have different economics.
A hospital may find it difficult to justify investing millions of dollars in specialised equipment that operates below capacity.
A central reference laboratory serving many hospitals can potentially operate that same equipment at significantly higher utilisation.
This is one of the structural forces that can encourage laboratory outsourcing and consolidation.
Laboratories Are Becoming Strategic M&A Assets
Traditionally, a laboratory might be viewed mainly as a medical facility.
From an investment perspective, however, a functioning laboratory business contains several valuable assets.
It may have recurring testing volumes.
It may have hospital and physician relationships.
It may have licenses, accreditation and trained personnel.
It may have established collection centres.
It may have logistics routes and sample-processing infrastructure.
It may also have specialist capabilities that are difficult and time-consuming to build.
That means a laboratory company can be more than a collection of analyzers.
It can be a strategic platform.
For larger diagnostic companies, acquiring an existing laboratory or selected laboratory assets can therefore be faster than building an equivalent network organically.
This helps explain why laboratory consolidation has become an important part of the growth strategy of companies such as Labcorp.
What Could This Mean for Vietnam?
The United States and Vietnam are very different diagnostic markets.
The structure, reimbursement systems, regulations and healthcare economics are not directly comparable.
However, the underlying economics of laboratory scale are relevant.
Vietnam’s diagnostic laboratory market remains relatively fragmented, with hospital laboratories representing the largest part of the market and independent laboratory networks competing alongside numerous smaller providers.
At the same time, the market is growing.
Ken Research estimates Vietnam’s diagnostic laboratory market at approximately US$1.12 billion in 2025, with the potential to reach approximately US$1.83 billion by 2031.
As testing volumes increase and specialised diagnostics become more important, laboratory operators may face increasing pressure to invest in technology, automation, logistics, quality management and specialist expertise.
Not every independent laboratory will necessarily be able — or need — to make all of those investments independently.
That creates several possible paths.
Some laboratory groups may expand organically and build larger networks.
Others may develop partnerships with hospitals and clinics.
Some may specialise in high-value areas such as oncology, genetics or molecular diagnostics.
And some laboratory owners may eventually decide that joining a larger diagnostic platform creates more value than remaining completely independent.
If that happens, the number of diagnostic M&A opportunities in Vietnam could increase.
Consolidation Does Not Necessarily Mean Fewer Laboratories
It is important to distinguish consolidation from physical centralisation.
A larger diagnostic group does not necessarily need fewer patient-facing locations.
In fact, it may need more.
Collection centres can remain distributed across cities and provinces while complex testing becomes increasingly centralised.
This creates a hub-and-spoke model.
Local clinics and collection centres provide convenient patient access.
Regional laboratories process higher-volume routine tests.
Central reference laboratories handle more complex and specialised diagnostics.
Samples move through the network while results are distributed digitally.
Under this model, consolidation happens primarily at the level of ownership, technology, quality systems, procurement and specialised testing infrastructure — not necessarily at the level of patient access.
That distinction could become particularly important in geographically dispersed markets.
What Investors Can Learn From Labcorp
Labcorp’s 2025 activity provides a useful signal for investors watching the diagnostic sector.
The company did not rely exclusively on building new laboratories.
It used acquisitions, asset purchases and partnerships to add testing volume, healthcare relationships and specialised capabilities to an existing platform.
That is fundamentally a network strategy.
And networks can create advantages that individual laboratories may find difficult to replicate.
The larger question for developing diagnostic markets is therefore not simply:
How many new laboratories will be built?
It may increasingly become:
Which laboratories will become part of larger networks?
For investors following healthcare in Vietnam and Southeast Asia, this makes diagnostics an unusually interesting sector to watch.
The opportunity is not only the growth of testing demand.
It is the potential consolidation of the businesses that perform those tests.
And if Vietnam’s laboratory industry gradually follows that direction, the next major opportunity may not be building another standalone laboratory.
It may be building — or acquiring — the network that connects them.